Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study

We performed this phase III study to determine whether the addition of 3 months of oral etoposide in non-progressing patients with extensive small-cell lung cancer (SCLC) treated with four cycles of etoposide plus ifosfamide plus cisplatin (VIP) improves progression-free survival (PFS) or overall su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2002, Vol.13 (1), p.95-102
Hauptverfasser:	HANNA, N. H, SANDLER, A. B, LOEHRER, P. J, ANSARI, R, JUNG, S. H, LANE, K, EINHORN, L. H
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Small Cell - drug therapy Chemotherapy Cisplatin - therapeutic use Disease Progression Etoposide - administration & dosage Etoposide - adverse effects Etoposide - therapeutic use Female Humans Ifosfamide - therapeutic use Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Survival Rate Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!